Following on from a recent European Academy of Neurology guideline on pharmacological treatment of multiple sclerosis (MS), the American Academy of Neurology has issued an updated practice guideline on disease-modifying therapies (DMTs) for MS. The guideline provides 30 general recommendations for initiating, switching and stopping DMTs, and indicates future research directions.
This is a preview of subscription content, log in via an institution to check access.
References
Baecher-Allan, C., Kaskow, B. J. & Weiner, H. L. Multiple sclerosis: mechanisms and immunotherapy. Neuron 97, 742–768 (2018).
Larochelle, C., Uphaus, T., Prat, A. & Zipp, F. Secondary progression in multiple sclerosis: neuronal exhaustion or distinct pathology? Trends Neurosci. 39, 325–339 (2016).
Rae-Grant, A. et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 90, 777–788 (2018).
Montalban, X. et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur. J. Neurol. 25, 215–237 (2018).
D’Amico, E., Zanghi, A., Leone, C., Tumani, H. & Patti, F. Treatment-related progressive multifocal leukoencephalopathy in multiple sclerosis: a comprehensive review of current evidence and future needs. Drug Saf. 39, 1163–1174 (2016).
Berger, J. R. et al. Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology 90, e1815–e1821 (2018).
Gieselbach, R. J. et al. Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases. J. Neurol. 264, 1155–1164 (2017).
Kalincik, T. et al. Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain 140, 2426–2443 (2017).
Disanto, G. et al. Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann. Neurol. 81, 857–870 (2017).
Siller, N. et al. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. Mult. Scler. https://doi.org/10.1177/1352458518765666 (2018).
Acknowledgements
The authors thank C. Ernest for proofreading the manuscript. The authors’ work is funded by the German Research Foundation (DFG) and the German Federal Ministry of Education and Research (BMBF).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.B. has recently received consultation funds from Merck Serono, Novartis, Sanofi-Aventis and Roche. F.Z. has recently received research grants from Genzyme and Merck Serono, as well as consultation funds from Roche, Merck Serono, Novartis, Sanofi-Aventis, Celgene and Octapharma.
Rights and permissions
About this article
Cite this article
Bittner, S., Zipp, F. AAN unveils new guidelines for MS disease-modifying therapy. Nat Rev Neurol 14, 384–386 (2018). https://doi.org/10.1038/s41582-018-0026-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-018-0026-7
- Springer Nature Limited
This article is cited by
-
Implications of immunometabolism for smouldering MS pathology and therapy
Nature Reviews Neurology (2023)
-
Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions
Neurological Research and Practice (2021)
-
Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper)
Der Nervenarzt (2021)
-
Implementing the 2017 McDonald criteria for the diagnosis of multiple sclerosis
Nature Reviews Neurology (2019)
-
Infektionen unter Immuntherapie zur Behandlung der multiplen Sklerose
DGNeurologie (2018)